Literature DB >> 20692338

The blood-brain barrier, chemokines and multiple sclerosis.

David W Holman1, Robyn S Klein, Richard M Ransohoff.   

Abstract

The infiltration of leukocytes into the central nervous system (CNS) is an essential step in the neuropathogenesis of multiple sclerosis (MS). Leukocyte extravasation from the bloodstream is a multistep process that depends on several factors including fluid dynamics within the vasculature and molecular interactions between circulating leukocytes and the vascular endothelium. An important step in this cascade is the presence of chemokines on the vascular endothelial cell surface. Chemokines displayed along the endothelial lumen bind chemokine receptors on circulating leukocytes, initiating intracellular signaling that culminates in integrin activation, leukocyte arrest, and extravasation. The presence of chemokines at the endothelial lumen can help guide the movement of leukocytes through peripheral tissues during normal immune surveillance, host defense or inflammation. The expression and display of homeostatic or inflammatory chemokines therefore critically determine which leukocyte subsets extravasate and enter the peripheral tissues. Within the CNS, however, infiltrating leukocytes that cross the endothelium face additional boundaries to parenchymal entry, including the abluminal presence of localizing cues that prevent egress from perivascular spaces. This review focuses on the differential display of chemokines along endothelial surfaces and how they impact leukocyte extravasation into parenchymal tissues, especially within the CNS. In particular, the display of chemokines by endothelial cells of the blood brain barrier may be altered during CNS autoimmune disease, promoting leukocyte entry into this immunologically distinct site. Recent advances in microscopic techniques, including two-photon and intravital imaging have provided new insights into the mechanisms of chemokine-mediated capture of leukocytes within the CNS. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692338      PMCID: PMC3005102          DOI: 10.1016/j.bbadis.2010.07.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  165 in total

1.  Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment.

Authors:  J Priller; A Flügel; T Wehner; M Boentert; C A Haas; M Prinz; F Fernández-Klett; K Prass; I Bechmann; B A de Boer; M Frotscher; G W Kreutzberg; D A Persons; U Dirnagl
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

2.  Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study.

Authors:  A M Butt; H C Jones; N J Abbott
Journal:  J Physiol       Date:  1990-10       Impact factor: 5.182

3.  Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells.

Authors:  Hooman Ranjbaran; Yinong Wang; Thomas D Manes; Alexander O Yakimov; Shamsuddin Akhtar; Martin S Kluger; Jordan S Pober; George Tellides
Journal:  Circulation       Date:  2006-08-28       Impact factor: 29.690

4.  Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl- current and chemotaxis in murine microglia.

Authors:  Angelika Rappert; Knut Biber; Christiane Nolte; Martin Lipp; Andreas Schubel; Bao Lu; Norma P Gerard; Craig Gerard; Hendrikus W G M Boddeke; Helmut Kettenmann
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

Review 5.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.

Authors:  T M Handel; Z Johnson; S E Crown; E K Lau; A E Proudfoot
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

6.  Glycosaminoglycans mediate cell surface oligomerization of chemokines.

Authors:  A J Hoogewerf; G S Kuschert; A E Proudfoot; F Borlat; I Clark-Lewis; C A Power; T N Wells
Journal:  Biochemistry       Date:  1997-11-04       Impact factor: 3.162

Review 7.  Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.

Authors:  Adam Szczuciński; Jacek Losy
Journal:  Acta Neurol Scand       Date:  2007-03       Impact factor: 3.209

8.  Margination of leukocytes in blood flow through small tubes.

Authors:  H L Goldsmith; S Spain
Journal:  Microvasc Res       Date:  1984-03       Impact factor: 3.514

9.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.

Authors:  Frederic Sierro; Christine Biben; Laura Martínez-Muñoz; Mario Mellado; Richard M Ransohoff; Meizhang Li; Blanche Woehl; Helen Leung; Joanna Groom; Marcel Batten; Richard P Harvey; Carlos Martínez-A; Charles R Mackay; Fabienne Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

10.  Segmental differentiations of cell junctions in the vascular endothelium. The microvasculature.

Authors:  M Simionescu; N Simionescu; G E Palade
Journal:  J Cell Biol       Date:  1975-12       Impact factor: 10.539

View more
  86 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.

Authors:  Michelle A Erickson; Kenji Dohi; William A Banks
Journal:  Neuroimmunomodulation       Date:  2012-01-11       Impact factor: 2.492

Review 3.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 4.  Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models.

Authors:  Yukio Takeshita; Richard M Ransohoff
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

5.  Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Kazuyuki Saito; Masa-aki Abe; Toshihiko Maeda; Hiroyo Haruki; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

Review 6.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

7.  Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern.

Authors:  A Jafarzadeh; S Bagherzadeh; H A Ebrahimi; H Hajghani; M R Bazrafshani; A Khosravimashizi; M Nemati; F Gadari; A Sabahi; F Iranmanesh; M M Mohammadi; H Daneshvar
Journal:  J Mol Neurosci       Date:  2014-01-07       Impact factor: 3.444

8.  An in vitro blood-brain barrier model combining shear stress and endothelial cell/astrocyte co-culture.

Authors:  Yukio Takeshita; Birgit Obermeier; Anne Cotleur; Yasuteru Sano; Takashi Kanda; Richard M Ransohoff
Journal:  J Neurosci Methods       Date:  2014-05-22       Impact factor: 2.390

9.  Systemic lipopolysaccharide compromises the blood-labyrinth barrier and increases entry of serum fluorescein into the perilymph.

Authors:  Keiko Hirose; Jared J Hartsock; Shane Johnson; Peter Santi; Alec N Salt
Journal:  J Assoc Res Otolaryngol       Date:  2014-06-21

10.  Alpha beta-crystallin expression and presentation following infection with murine gammaherpesvirus 68.

Authors:  Vinita S Chauhan; Daniel A Nelson; Ian Marriott; Kenneth L Bost
Journal:  Autoimmunity       Date:  2013-04-16       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.